Naltrexone for treatment of impaired awareness of hypoglycemia in type 1 diabetes: A randomized clinical trial

AIMS: Impaired awareness of hypoglycemia (IAH) is a limiting factor in the treatment of type 1 diabetes (T1D) and is a challenging condition to reverse. The objective of this study was to test the hypothesis that naltrexone therapy in subjects with T1D and IAH will improve counterregulatory hormone...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Diabetes Complications
Egile Nagusiak: Moheet, Amir, Mangia, Silvia, Kumar, Anjali, Tesfaye, Nolawit, Eberly, Lynn E, Bai, Yun, Kubisiak, Kristine, Seaquist, Elizabeth R
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2015
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4871128/
https://ncbi.nlm.nih.gov/pubmed/26345338
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jdiacomp.2015.08.004
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak